Trial Name
and Design |
Cell Line |
Sample Size
(n) |
Cell Dose |
Days to Admin Post MI |
Route of Admin |
Imaging
Modality |
Primary End Point |
LEUVEN-AMI [47]
(RCT 2006) |
BMC |
67 |
3.0 ± 1.3 × 108 |
<24 hours |
IC |
MRI |
•No increase in EF over control (At 4 months)
•Possible decrease in infarct size
|
ASTAMI [48]
(RCT 2006) |
BMC |
100 |
0.68 × 108 (median) |
6 ± 1 |
IC |
SPECT |
•No increase in EF over control
(At 6 months) |
REGENT [38]
(RCT 2009) |
BMC or
CD34/CXCR4 |
200 |
BMC: 1.78 × 108 (median)
CD34/CXCR4: 0.019 × 108 (median) |
3-12 |
IC |
MRI |
•No increase in EF over control
|
HEBE [39]
(RCT 2010) |
BMC or
mPBC |
200 |
BMC: 3 ± 1.6 × 108
mPBC: 2.9 ± 1.4 × 108 |
3-8 |
IC |
MRI |
•No increase in EF over control
(At 4 months) |
BONAMI [49] (RCT 2009) |
BMC |
101 |
0.98 ± 0.09 × 108 |
9.3 ± 1.7 |
IC |
SPECT
RNA
MRI
ECHO |
•No increase in EF over control
•No decrease in infarct size
(At 3 months) |
CADUCEUS [46]
(RCT 2012) |
CDC |
31 |
12.5-25 × 106 |
1.5–3 mths |
IC |
MRI |
•No increase in EF over control
(At 6 months) |